Postoperative pancreatic fistulas decrease the survival of pancreatic cancer patients treated with surgery after neoadjuvant chemoradiotherapy: A retrospective analysis.


Journal

Surgical oncology
ISSN: 1879-3320
Titre abrégé: Surg Oncol
Pays: Netherlands
ID NLM: 9208188

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 16 08 2020
revised: 13 10 2020
accepted: 19 10 2020
pubmed: 8 11 2020
medline: 9 10 2021
entrez: 7 11 2020
Statut: ppublish

Résumé

A postoperative pancreatic fistula (POPF) is a critical complication after surgery for pancreatic cancer. Whether a POPF affects the long-term prognosis of pancreatic cancer cases remains controversial. This study aimed to clarify the effect of a POPF on the long-term prognosis of pancreatic cancer patients, especially after neoadjuvant chemoradiotherapy (NACRT). Patients who underwent curative pancreatectomy for pancreatic cancer between January 2012 and June 2019 at Kyoto University Hospital were retrospectively investigated. A fistula ≥ Grade B was considered a POPF. During the study period, 148 patients underwent upfront surgery (Upfront group), and 52 patients underwent surgery after NACRT (NACRT group). A POPF developed in 16% of patients in the Upfront group and 13% in the NACRT group (p = 0.824). In the Upfront group, development of a POPF did not have a significant effect on recurrence-free survival (p = 0.766) or overall survival (p = 0.863). However, in the NACRT group, development of a POPF significantly decreased recurrence-free survival (HR 5.856, p = 0.002) and overall survival (HR 7.097, p = 0.020) on multivariate analysis. The development of a POPF decreases the survival of pancreatic cancer patients treated by surgery after NACRT.

Sections du résumé

BACKGROUND AND OBJECTIVES OBJECTIVE
A postoperative pancreatic fistula (POPF) is a critical complication after surgery for pancreatic cancer. Whether a POPF affects the long-term prognosis of pancreatic cancer cases remains controversial. This study aimed to clarify the effect of a POPF on the long-term prognosis of pancreatic cancer patients, especially after neoadjuvant chemoradiotherapy (NACRT).
METHODS METHODS
Patients who underwent curative pancreatectomy for pancreatic cancer between January 2012 and June 2019 at Kyoto University Hospital were retrospectively investigated. A fistula ≥ Grade B was considered a POPF.
RESULTS RESULTS
During the study period, 148 patients underwent upfront surgery (Upfront group), and 52 patients underwent surgery after NACRT (NACRT group). A POPF developed in 16% of patients in the Upfront group and 13% in the NACRT group (p = 0.824). In the Upfront group, development of a POPF did not have a significant effect on recurrence-free survival (p = 0.766) or overall survival (p = 0.863). However, in the NACRT group, development of a POPF significantly decreased recurrence-free survival (HR 5.856, p = 0.002) and overall survival (HR 7.097, p = 0.020) on multivariate analysis.
CONCLUSIONS CONCLUSIONS
The development of a POPF decreases the survival of pancreatic cancer patients treated by surgery after NACRT.

Identifiants

pubmed: 33160278
pii: S0960-7404(20)30418-7
doi: 10.1016/j.suronc.2020.10.010
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

527-532

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Yuichiro Uchida (Y)

Division of Hepatobiliary Pancreatic Surgery and Transplantation, Department of Surgery, Kyoto University Hospital, Japan; Department of Surgery, Fujita Medical University Hospital, Japan.

Toshihiko Masui (T)

Division of Hepatobiliary Pancreatic Surgery and Transplantation, Department of Surgery, Kyoto University Hospital, Japan. Electronic address: tmasui@kuhp.kyoto-u.ac.jp.

Kazuyuki Nagai (K)

Division of Hepatobiliary Pancreatic Surgery and Transplantation, Department of Surgery, Kyoto University Hospital, Japan.

Takayuki Anazawa (T)

Division of Hepatobiliary Pancreatic Surgery and Transplantation, Department of Surgery, Kyoto University Hospital, Japan.

Michio Yoshimura (M)

Department of Radiation Oncology and Image-applied Therapy, Kyoto University Hospital, Japan.

Norimitsu Uza (N)

Department of Gastroenterology and Hepatology, Kyoto University Hospital, Japan.

Kyoichi Takaori (K)

Division of Hepatobiliary Pancreatic Surgery and Transplantation, Department of Surgery, Kyoto University Hospital, Japan.

Takashi Mizowaki (T)

Department of Surgery, Fujita Medical University Hospital, Japan.

Shinji Uemoto (S)

Division of Hepatobiliary Pancreatic Surgery and Transplantation, Department of Surgery, Kyoto University Hospital, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH